Loop Capital analyst Alan Gould maintains Snap (NYSE:SNAP) with a Buy and lowers the price target from $26 to $19.
PharmaCyte Biotech Announces Cash Tender Offer For Up To 7.75M Shares At $3.25 Per Share
Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 per Share
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the